Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Jun;27(6):1007-1015.
doi: 10.1002/ejhf.3670. Epub 2025 May 20.

Recurrent event analyses in patients receiving maintenance dialysis and the effect of higher- versus lower-dose chronic intravenous iron therapy: A report focusing on heart failure events from the PIVOTAL trial

Stefan D Anker  1 , Michele Robertson  2 , John J V McMurray  3 , Pardeep S Jhund  3 , Claire White  4 , Chante Reid  4 , Sunil Bhandari  5 , Ken Farrington  6 , Philip A Kalra  7 , Khawaja M Talha  8 , Patrick B Mark  3 , Charles R V Tomson  9 , David C Wheeler  10 , Chris G Winearls  11 , Iain C Macdougall  4 , Ian Ford  2
Affiliations
Randomized Controlled Trial

Recurrent event analyses in patients receiving maintenance dialysis and the effect of higher- versus lower-dose chronic intravenous iron therapy: A report focusing on heart failure events from the PIVOTAL trial

Stefan D Anker et al. Eur J Heart Fail. 2025 Jun.

Abstract

Aims: In the PIVOTAL trial, a proactive high-dose regimen of intravenous iron sucrose, compared to a lower-dose reactive regimen, reduced the risk of first and recurrent events of the primary endpoint in haemodialysis patients. We present the various approaches of recurrent event analyses for the primary endpoint and for the composite of cardiovascular (CV) death or heart failure hospitalization and their non-fatal components.

Methods and results: Patients were randomized to a proactive maintenance dose of iron sucrose (average 264 mg/month) or a reactive treatment regimen (average 145 mg/month). We compared the results of time-to-first event analyses with recurrent event analysis using the negative binomial model and methods proposed by Wei-Lin-Weissfeld, Andersen and Gill, Lin, Wei, Yang and Ying [LWYY], Mao and Lin, and Rondeau and colleagues. The 2141 haemodialysis patients were followed for a median of 2.1 years and experienced 936 primary recurrent events, which is 42% higher than the number of 658 first events. Proactive regimen patients had 429 primary events (19.4/100 patient-years) compared with 507 events in the reactive regimen patients (24.6/100 patient-years) (rate ratio 0.77, 95% confidence interval [CI] 0.66-0.92, p = 0.0027, LWYY). Recurrent events were also reduced in the proactive regimen for the composite of CV mortality and heart failure hospitalizations (rate ratio 0.73, 95% CI 0.56-0.93, p = 0.013). Recurrent event analyses based on other approaches were very similar to those given above based on the method of LWYY.

Conclusion: A higher dose of chronic intravenous iron therapy compared to a lower dose substantially reduced the total burden of important recurrent events of death and CV disease in patients with end-stage kidney disease receiving maintenance haemodialysis therapy.

Keywords: Chronic kidney disease; Clinical trial; Iron deficiency; Recurrent events.

PubMed Disclaimer

References

    1. Yang W, Jepson C, Xie D, Roy JA, Shou H, Hsu JY, et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Statistical methods for recurrent event analysis in cohort studies of CKD. Clin J Am Soc Nephrol 2017;12:2066–2073. https://doi.org/10.2215/CJN.12841216
    1. Anker SD, McMurray JJ. Time to move on from ‘time‐to‐first’: Should all events be included in the analysis of clinical trials? Eur Heart J 2012;33:2764–2765. https://doi.org/10.1093/eurheartj/ehs277
    1. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al.; PIVOTAL Investigators and Committees. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019;380:447–458. https://doi.org/10.1056/NEJMoa1810742
    1. Rogers JK, Yaroshinsky A, Pocock SJ, Stokar D, Pogoda J. Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model. Stat Med 2016;35:2195–2205. https://doi.org/10.1002/sim.6853
    1. Claggett B, Pocock S, Wei LJ, Pfeffer, McMurray JJV, Solomon SD. Comparison of time‐to first event and recurrent‐event methods in randomized clinical trials. Circulation 2018;138:570–577. https://doi.org/10.1161/CIRCULATIONAHA.117.033065

Publication types

MeSH terms

LinkOut - more resources